CST6 may function as a prognostic biomarker for HCC, with a high CST6 expression being associated with poor survival of patients, in correlation with a previous report claiming that cystatin M/E could be a pancreatic tumor promotor [119]. This evidence concerns the gene CST6 and hepatocellular carcinoma.